Effects of atorvastatin versus probucol on low-density lipoprotein subtype distribution and renal function in hyperlipidemic patients with nondiabetic nephropathy

Renal Failure

Volumn 32, Issue 6, 2010, Pages 680-686

  Yasuda, Gen ^a   Ando, Daisaku ^a   Hirawa, Nobuhito ^a   Umemura, Satoshi ^b  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Albuminuria; Glomerulonephritis; Hypercholesterolemia; Lipids; Renoprotection

Indexed keywords

ALBUMIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; CREATININE; LOW DENSITY LIPOPROTEIN; PROBUCOL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CREATININE URINE LEVEL; CROSSOVER PROCEDURE; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY INJURY; LIPID BLOOD LEVEL; MALE; PARTICLE SIZE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; URINARY EXCRETION; URINE LEVEL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CROSS-OVER STUDIES; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; KIDNEY DISEASES; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PARTICLE SIZE; PROBUCOL; PROSPECTIVE STUDIES; PYRROLES; YOUNG ADULT;

EID: 77953586689     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2010.486493     Document Type: Article

References (31)

1. US Renal Data System. Causes of death. Am J Kidney Dis. 1998;32(Suppl. 1):S81-S88.
2. Attman PO, Alaupovic P, Samuelsson O. Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease. Kidney Int. 1999;56(Suppl. 71):S14-S17.
3. Wheeler DC, Chana RS, Topley N, Petersen MM, Davies M, Wlliams JD. Oxidation of low density lipoprotein by mesangial cells may promote glomerular injury. Kidney Int. 1994;45:1628-1636.
4. Rie J, Silbiger S, Neugarten J. Glomerular macrophages in nephrotoxic serum nephritis are activated to oxidize low-density lipoprotein. Am J Kidney Dis. 1995;26:362-367.
5. Nishida Y, Oda H, Yorioka N. Effect of lipoproteins on mesangial cell proliferation. Kidney Int. 1999;56(Suppl. 71):S51-S53.
6. Dejager S, Bruckert E, Chapman MJ. Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res. 1993;34:295-308.
7. Chan PCK, Robinson JD, Yeung WC, Cheng IKP, Yeung HWD, Tsang MTS. Lovastatin in glomerulonephritis patients with hyperlipidaemia and heavy proteinuria. Nephrol Dial Transplant. 1992;7:93-99.
8. Buemi M, Allegra A, Corica F, et al. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clin Pharmacol Ther. 2000;67:427-431.
9. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003;41:565-570.
10. Lee HS, Jeong JY, Kim BC, Kim YS, Zhang YZ, Chung HK. Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis. Kidney Int. 1997;51:1151-1159.
11. Mune M, Meydani M, Gong J, et al. Effect of dietary fish oil, vitamin E, and probucol on renal injury in the rat. J Nutr Biochem. 1999;10:539-546.
12. Yoshinari M, Shi AH, Yoshizumi H, Wakisaka M, Iwase M, Fujishima M. Probucol reduces lysophosphatidylcholines in lowdensity lipoprotein. Eur J Clin Pharmacol. 2000;55:787-792.
13. Pontrelli L, Parris W, Adeli K, Cheung RC. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/Type 2 diabetes. Metabolism. 2002;51:334-342.
14. Friedewald WT, Levy RI, Fredrickson DS. Estimate of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-504.
15. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res. 1982;23:97-104.
16. Ikejiri A, Hirano T, Murayama S, et al. Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients. Metabolism. 2004;53:1113-1117.
17. Fathi R, Isbel N, Short L, et al. The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease. Am J Kidney Dis. 2004;43:45-52.
18. Melenovsky V, Malik J, Wichterle D, et al. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am Heart J. 2002;144:G1-G8.
19. Baldassarre D, Franceschini G, Peruzzotti G, Brusoni B, Sirtori CR. Clinical evaluation of probucol in hypercholesterolemia: Individual lipoprotein responses and inhibitory effect on carotid atherosclerosis progression. J Cardiovasc Pharmacol. 1997;30:784-789.
20. Thomas ME, Harris KPG, Ramaswamy C, et al. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney Int. 1993;44:1124-1129.
21. van Dijk MA, Kamper AM, van Veen S, Souverijn JHM, Blauw GJ. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2001;16:2152-2157.
22. Yasuda G, Kuji T, Hasegawa K, et al. Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease. Ren Fail. 2004;26:411-418.
23. Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D. Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest. 1986;77:641-644.
24. Haas M, Kerjashki D, Mayer G. Lipid-lowering therapy in membranous nephropathy. Kidney Int. 1999;56(Suppl. 71):S110-S112.
25. Kaplan R, Aynedjian HS, Schlondorff D, Bank N. Renal vasoconstriction caused by short-term cholesterol feeding is corrected by thromboxane antagonist or probucol. J Clin Invest. 1990;86:1707-1714.
26. O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest. 1993;91:83-87.
27. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004;57:728-734.
28. Galle J, Heermeier K. Angiotensin II and oxidized LDL: An unholy alliance creating oxidative stress. Nephrol Dial Transplant. 1999;14:2585-2589.
29. Brenner BM, Cooper ME, de Zeeuw D, et al.. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
30. Yasuda G, Ando D, Hirawa N, Umemura S, Tochikubo O. Effects of losartan and amlodipine on urinary albumin excretion and ambulatory blood pressure in hypertensive type 2 diabetic patients with overt nephropathy. Diabetes Care. 2005;28:1862-1868. (Pubitemid 41060955)
31. Hommel E, Andersen P, Gall MA, et al.. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia. 1992;35:447-451.